Article
Oncology
Alessandro Ottaiano, Mariachiara Santorsola, Paola Del Prete, Francesco Perri, Stefania Scala, Michele Caraglia, Guglielmo Nasti
Summary: High expression of CXCR4 is clearly associated with increased risk of death and progression in colorectal cancer. However, methodologic heterogeneity in CXCR4 assessment hinders direct translation into clinical practice, indicating the need for a consensus to streamline detection and scoring of CXCR4 expression in colorectal cancer.
Article
Cell Biology
Shiqing Liu, Chengping Hu, Min Li, Jian An, Wolong Zhou, Jia Guo, Yao Xiao
Summary: This study reveals that estrogen receptor beta promotes non-small-cell lung cancer cell invasion through regulating the circ-TMX4/miR-622/CXCR4 signaling pathway. These findings provide a new target for the development of treatment strategies to suppress lung cancer progression.
CELL DEATH & DISEASE
(2022)
Article
Biochemistry & Molecular Biology
Takumi Tsunoda, Miho Riku, Norika Yamada, Hikaru Tsuchiya, Takuya Tomita, Minako Suzuki, Mari Kizuki, Akihito Inoko, Hideaki Ito, Kenta Murotani, Hideki Murakami, Yasushi Saeki, Kenji Kasai
Summary: HECT-type ubiquitin E3 ligases, such as ITCH, play important roles in cellular functions by ubiquitinating various substrates. FAM189A2, a downregulated gene in breast cancer, acts as a unique activator for ITCH to regulate CXCR4 activity in endosomes, influencing chemotaxis and mammosphere formation of breast cancer cells.
Article
Chemistry, Multidisciplinary
Abraham Akonnor, Masaki Makise, Akihiko Kuniyasu
Summary: A CXCR4-targeted antitumor peptidomimetic (CTCE-KLAK) was developed and showed cell-selective cytotoxicity against breast cancer cells and induced rapid necrotic cell death. In a mouse model, CTCE-KLAK significantly inhibited tumor growth and lung metastasis, highlighting its potential as a promising agent for treating triple-negative breast cancer.
Article
Biochemistry & Molecular Biology
Maria Neves, Viviana Marolda, Federico Mayor, Petronila Penela
Summary: A better understanding of the crosstalk between key receptors and signaling pathways involved in cancer progression, specifically in breast cancer subtypes, is crucial for improving current therapies and addressing tumor microenvironment. This study examines the interplay between CXCR4/ACKR3 chemokine receptors and EGFR family signaling pathways in different breast cancer cell models and highlights their cooperation in promoting ERK1/2 activation, with potential implications for cancer progression.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Oncology
Chun-Wen Cheng, Wen-Ling Liao, Po-Ming Chen, Jyh-Cherng Yu, Hui-Ping Shiau, Yi-Hsien Hsieh, Huei-Jane Lee, Yu-Chun Cheng, Pei-Ei Wu, Chen-Yang Shen
Summary: The study demonstrates that miR-139 can suppress invasion and migration of breast cancer stem cells by down-regulating CXCR4/p-Akt signaling, and its reduced expression is associated with worse clinicopathological features in breast cancer patients, suggesting it as a potential therapeutic target for invasive breast cancer.
Article
Immunology
Shuai Xue, Ming Ma, Songhua Bei, Fan Li, Chenqu Wu, Huanqing Li, Yanling Hu, Xiaohong Zhang, YanQing Qian, Zhe Qin, Jun Jiang, Li Feng
Summary: This study established a prognostic model of gastric cancer based on the expression profile of immunoregulatory factor-related genes using TCGA database. CXCR4 was identified as an independent prognostic indicator for gastric cancer patients, involved in the progression of gastric cancer and associated with poor survival. Functional studies demonstrated that CXCR4 promoted the proliferation, migration, and invasion of gastric cancer cells.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Oncology
Liping Qiu, Yuanyuan Xu, Hui Xu, Biyun Yu
Summary: High expression of CXCR4 in lung cancer is associated with poor overall survival and disease-free survival. It is significantly correlated with poor overall survival in non-small cell lung cancer patients and patients showing CXCR4 expression in the cytoplasm and the membrane.
Article
Biology
Valentina Poltavets, Jessica W. Faulkner, Deepak Dhatrak, Robert J. Whitfield, Shaun R. McColl, Marina Kochetkova
Summary: The CXCR4 and CCR7 receptor ligands, CXCL12 and CCL19, cooperatively bind and selectively elicit synergistic signaling responses in invasive breast cancer cell lines and primary mammary human tumor cells. The presence of CXCR4-CCR7 heterodimers in advanced primary mammary mouse and human tumors directly correlates with the severity of the disease, and their forced heterodimerization leads to the acquisition of invasive phenotype in non-metastatic breast cancer cells. These findings establish the CXCR4-CCR7 receptor complex as a new functional unit responsible for the acquisition of breast cancer cell metastatic phenotype and a potential novel biomarker for invasive mammary tumors.
Article
Medicine, Research & Experimental
Migara Kavishka Jayasinghe, Marco Pirisinu, Yuqi Yang, Boya Peng, Thach Tuan Pham, Chang Yu Lee, Melissa Tan, Luyen Tien Vu, Xuan T. T. Dang, Tin Chanh Pham, Huan Chen, Anskar Y. H. Leung, William C. Cho, Jiahai Shi, Minh T. N. Le
Summary: The use of extracellular vesicles (EVs) as drug delivery vectors has gained attention due to their ability to efficiently deliver therapeutic payloads to diseased cells. Surface functionalization methods have been developed to enhance the stability and biocompatibility of EVs, allowing for targeted delivery to cancer cells and improved metastasis suppression. Extensive testing has shown that engineered EVs are biocompatible and safe for repeated dose treatment.
Article
Oncology
Jose Pablo Leone, Michael J. Hassett, Julieta Leone, Sara M. Tolaney, Carlos T. Vallejo, Bernardo A. Leone, Eric P. Winer, Nancy U. Lin
Summary: This study compares the proportions of pathologic complete response (pCR) between male breast cancer (MaBC) and female breast cancer (FBC) in neoadjuvant chemotherapy (NAC), and finds that FBC has higher pCR rates. Furthermore, pCR is associated with survival rates in both MaBC and FBC.
Article
Medicine, General & Internal
Timothy J. Whelan, Sally Smith, Sameer Parpia, Anthony W. Fyles, Anita Bane, Fei-Fei Liu, Eileen Rakovitch, Lynn Chang, Christiaan Stevens, Julie Bowen, Sawyna Provencher, Valerie Theberge, Anna Marie Mulligan, Zuzana Kos, Mohamed A. Akra, K. David Voduc, Tarek Hijal, Ian S. Dayes, Gregory Pond, James R. Wright, Torsten O. Nielsen, Mark N. Levine
Summary: Among women with T1N0 grade 1 or 2 luminal A breast cancer who had undergone breast-conserving surgery and received endocrine therapy, the incidence of local recurrence at 5 years was low without radiotherapy.
NEW ENGLAND JOURNAL OF MEDICINE
(2023)
Review
Oncology
Shunshun Bao, Mohammad Darvishi, Ali Amin, Maysoon T. Al-Haideri, Indrajit Patra, Khadisha Kashikova, Irfan Ahmad, Fahad Alsaikhan, Zahraa Haleem Al-qaim, Moaed E. Al-Gazally, Bahman Abedi Kiasari, Bahareh Tavakoli-Far, Akmal A. Sidikov, Yasser Fakri Mustafa, Reza Akhavan-Sigari
Summary: CXC chemokine receptor type 4 (CXCR4) is a G protein-coupled receptor that interacts with its ligand CXCL12 to trigger downstream signaling pathways. This interaction plays a key role in tumor progression and is involved in processes such as tumor growth, angiogenesis, metastasis, and therapeutic resistance. CXCR4-targeting compounds have shown promising anti-tumor activity and have potential as therapeutic options for cancer treatment. This review focuses on the physiological signaling of the CXCL12/CXCR4 axis, its role in tumor progression, and strategies to block CXCR4.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2023)
Article
Multidisciplinary Sciences
Brock A. Humphries, Anne Zhang, Johanna M. Buschhaus, Avinash Bevoor, Alex Farfel, Shrila Rajendran, Alyssa C. Cutter, Gary D. Luker
Summary: Reactive oxygen species (ROS) produced by mitochondria can affect intracellular ROS levels in cancer cells. Increasing ROS levels through promoting mitochondrial fission inhibits cell migration in triple negative breast cancer (TNBC).
Article
Oncology
Sidar Bagbudar, Hasan Karanlik, Neslihan Cabioglu, Aysel Bayram, Mustafa Tuekenmez, Adnan Aydiner, Ekrem Yavuz, Semen Onder
Summary: This study retrospectively evaluated the clinicopathological characteristics of MBC patients and assessed the immune density, expression of PD-L1 and CXCR4, and TILs. The results suggest that TILs and PD-L1 may have prognostic implications, providing a rationale for further studies on immune-targeting therapies.
Article
Multidisciplinary Sciences
Binglong Bai, Wuzhen Chen
SCIENTIFIC REPORTS
(2018)
Review
Immunology
Hailin Xu, Jingxin Jiang, Wuzhen Chen, Wenlu Li, Zhigang Chen
JOURNAL OF IMMUNOLOGY RESEARCH
(2019)
Review
Oncology
Wu-Zhen Chen, Jing-Xin Jiang, Xiu-Yan Yu, Wen-Jie Xia, Peng-Xin Yu, Ke Wang, Zhi-Yong Zhao, Zhi-Gang Chen
WORLD JOURNAL OF GASTROINTESTINAL ONCOLOGY
(2019)
Article
Medicine, Research & Experimental
Dan Xue, Pu Cheng, Jinxin Jiang, Yunqing Ren, Dang Wu, Wuzhen Chen
MEDICAL SCIENCE MONITOR
(2020)
Article
Cell Biology
Wuzhen Chen, Pu Cheng, Jingxin Jiang, Yunqing Ren, Dang Wu, Dan Xue
Review
Immunology
Wei Zhang, Yimin Shen, Huanhuan Huang, Sheng Pan, Jingxin Jiang, Wuzhen Chen, Ting Zhang, Chao Zhang, Chao Ni
FRONTIERS IN IMMUNOLOGY
(2020)
Article
Oncology
Zhen Wang, Chenghui Yang, Lili Li, Zhigang Zhang, Jun Pan, Ke Su, Wuzhen Chen, Jinfan Li, Fuming Qiu, Jian Huang
FRONTIERS IN ONCOLOGY
(2020)
Review
Cell Biology
Lesang Shen, Yunxiang Zhou, Haifei He, Wuzhen Chen, Cameron Lenahan, Xiaoyi Li, Yongchuan Deng, Anwen Shao, Jian Huang
Summary: Leukocytes and iron metabolism play important roles in tumorigenesis, with interplay in the tumor microenvironment. Combining immunotherapy with targeted regulation of iron metabolism may be a future research focus.
OXIDATIVE MEDICINE AND CELLULAR LONGEVITY
(2021)
Editorial Material
Medicine, General & Internal
Wu-Zhen Chen, Jing-Xin Jiang, Shan-Shan Sun, Xiu-Yan Yu, Jian Huang
CHINESE MEDICAL JOURNAL
(2021)
Review
Medicine, General & Internal
Mengjie Jiang, Wuzhen Chen, Yujie Hu, Chao Chen, Huafeng Li
Summary: The study suggests that OFS+TAM may be more beneficial than OFS+AI for premenopausal HR+ breast cancer patients. A 2-year course of OFS+TAM could achieve clinical benefit while the optimal course of OFS+AI still requires further study. Stage III patients are more suitable for OFS-based therapy.
Review
Oncology
Wuzhen Chen, Lesang Shen, Jingxin Jiang, Leyi Zhang, Zhigang Zhang, Jun Pan, Chao Ni, Zhigang Chen
Summary: Combining antiangiogenic therapy with immunotherapy may disrupt the crosstalk between abnormal tumor vasculature and immunosuppression, increase effector immune cell infiltration, improve immunotherapy effectiveness, and reduce the risk of immune-related adverse events. This combination could serve as a potential therapeutic strategy for breast cancer treatment, promoting tumor vasculature normalization and enhancing the efficiency of immunotherapy.
BIOMARKER RESEARCH
(2021)
Article
Oncology
Wuzhen Chen, Baizhou Li, Fang Jia, Jiaxin Li, Huanhuan Huang, Chao Ni, Wenjie Xia
Summary: The study revealed that high expression of PANX1 is associated with high tumor-associated neutrophil (TAN) infiltration and adenosine production, leading to local immunosuppression in basal-like breast cancer.
Review
Oncology
Leyi Zhang, Jun Pan, Wuzhen Chen, Jinxin Jiang, Jian Huang
AMERICAN JOURNAL OF CANCER RESEARCH
(2020)
Article
Biochemistry & Molecular Biology
Chao Ni, Qing-Qing Fang, Wu-Zhen Chen, Jin-Xing Jiang, Zhou Jiang, Jun Ye, Ting Zhang, Liu Yang, Fan-Bo Meng, Wen-Jie Xia, Miaochun Zhong, Jian Huang
SIGNAL TRANSDUCTION AND TARGETED THERAPY
(2020)
Article
Oncology
Jingxin Jiang, Weiwei Pan, Yazhang Xu, Chao Ni, Dan Xue, Zhigang Chen, Wuzhen Chen, Jian Huang
